Episode 3: A View On: mRNA Encapsulation
Driving Innovation Through Collaboration: The Future of mRNA Therapies
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bern-hard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how ad-vanced fluidics, encapsulation techniques, and a truly collaborative approach are paving the way for potential solid-tumor vaccines now in preclinical trials.
When you think about mRNA-based vaccines, have you ever considered the complex route these microscopic instructions must travel to deliver their life-changing code? This journey, essential for the therapy’s success, lies at the core of pharmaceutical research—where the challenge is to maximize stability and “bioavailability” so that each dose effec-tively reaches its cellular target.
By enclosing mRNA within lipid nanoparticles (LNPs) using sophisticated mixing tech-nologies, scientists can create the next generation of therapies—tailored to each patient’s needs. From prophylactic vaccines to personalized cancer treatments for solid tumors, these breakthroughs promise not only more effective but also safer medical solutions. In this episode, we spotlight FDmiX®, a groundbreaking mixer platform that enables the pre-cise production of LNPs, driving forward the possibility of new, life-saving vaccines in the fight against cancer.
Curious to Learn More?
Join us in this conversation hosted by Martina Ribar Hestericová, featuring Fraunhofer IPK’s Christoph Hein, FDX Fluid Dynamix’s Bernhard Bobusch, and Lonza’s Sönke Stocker, as they unveil how FDmiX® and mRNA encapsulation could revolutionize the development of solid-tumor vaccines and other cutting-edge therapies.